Health Condition 1: K228- Other specified diseases of esophagus
Conditions
Interventions
Intervention1: Cytosponge (an encapsulated sponge).: In this study, participants will swallow Cytosponge (an encapsulated sponge). Their acceptability to this method will be recorded as per Visual Ana
Sponsors
TATA Memorial Centre
Boston Medical University
Eligibility
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of esophageal squamous cell carcinoma Minimal or grade I dysphagia â?? defined as ability to swallow solids and semisolids If prior endoscopy done outside, gap between endoscopy and capsule swallow should be at least 7 days or more. Willing to undergo an additional procedure (sponge cytology) in addition to endoscopy for cancer diagnosis
Exclusion criteria
Exclusion criteria: Patients with dysphagia to solids, inability to swallow tablets, current head and neck or upper aerodigestive tract cancer, esophageal varices, cirrhosis or portal hypertension, severe pulmonary disease, stroke or myocardial infarction in the past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| acceptability and tolerability of cytosponge study in esophagus cancer patientsTimepoint: Same day as of procedure- Acceptibility and tolerability will be assessed with Visual Analogue Scale immediately after procedure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Use of sponge cytology in diagnosis of squamous cell carcinoma of esophagus. Tolerability of this procedure when compared of esophagoduodenoscopy.Timepoint: Within 2 weeks of procedure- Cytology result will be available within 2 weeks | — |
Countries
India
Contacts
Public ContactSabita Jiwnani
TATA MEMORIAL CENTRE
Outcome results
None listed